Standout Papers

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of... 2021 2026 2022 2024226
  1. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma (2021)
    Uğur Şahin, Ö. Türeci et al. Annals of Oncology

Immediate Impact

1 by Nobel laureates 7 from Science/Nature 59 standout
Sub-graph 1 of 23

Citing Papers

Computational design of soluble and functional membrane protein analogues
2024 StandoutNatureNobel
Oesophageal cancer
2024 Standout
2 intermediate papers

Works of Kai Wiechen being referenced

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
2021 Standout
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
2019

Author Peers

Author Last Decade Papers Cites
Kai Wiechen 528 89 326 374 22 1.2k
Xiaowu Gu 479 64 336 207 23 1.0k
Elena Loukinova 595 31 468 204 17 1.3k
Denis Tvorogov 834 86 672 160 28 1.4k
Hiroki Odagiri 707 55 380 165 34 1.3k
Mona Cornwell 671 46 154 223 34 1.3k
Yann Wallez 749 32 225 215 23 1.2k
Laura Gualandi 955 95 317 152 14 1.3k
Ariane Galaup 658 48 148 139 17 1.3k
Valentina Pirazzoli 767 61 558 117 13 1.4k
Zhenhua Zhai 670 54 464 68 21 1.3k

All Works

Loading papers...

Rankless by CCL
2026